Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product aids in lung function by reducing surface tension, facilitating breathing. Manufactured by Chiesi Farmaceutici S.P.A., it is essential for neonatal intensive care units.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the baby's lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, medical professionals aim to improve lung compliance and oxygenation, making it easier for the infant to breathe. The therapy is crucial for supporting the respiratory system during critical developmental stages.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This action can lead to improved lung function and easier breathing for premature infants. The effects are typically observed shortly after administration, providing immediate support to the respiratory system.

Curosurf should be administered by trained medical professionals in a controlled environment, such as a neonatal intensive care unit. It is essential to follow proper handling and storage guidelines to maintain the product's efficacy. Patients with known allergies to any of the components should avoid using Curosurf. Always consult healthcare providers for personalized advice.

Curosurf is generally used in a controlled medical setting, and interactions with other medications are rare. However, it is important to inform healthcare providers about any other treatments the infant is receiving. Always follow the guidance of medical professionals to ensure safe and effective use.